🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Which European ePharmacy stock you should own?

Published 02/10/2024, 14:30
© Reuters.
RDC
-
DOCM
-

Investing.com -- When considering which European ePharmacy stock to own, the latest market dynamics suggest a clear preference for Redcare Pharmacy (ETR:RDC) over DocMorris (SIX:DOCM). 

Analysts at HSBC (LON:HSBA) have updated their recommendations in a note dated Wednesday, reflecting the diverging performances and prospects of these two players in the European ePharmacy space.

Redcare Pharmacy has consistently shown strong momentum, particularly in its over-the-counter business, where it has delivered strong growth for twelve consecutive quarters. 

This contrasts sharply with DocMorris, which has struggled with weaker-than-expected results in the burgeoning eRx market, especially in Germany. 

HSBC analysts point to the stark gap in growth between the two companies, with Redcare Pharmacy outperforming DocMorris, both in terms of revenue and operating metrics. 

This outperformance has driven HSBC to upgrade Redcare Pharmacy’s stock to "buy" from "hold," increasing its target price to €155​ from €140.

Redcare Pharmacy's competitive edge appears to stem from its marketing strategy, particularly its celebrity-focused advertising campaigns, which have resonated well with consumers. 

This has allowed Redcare Pharmacy to capture more market share in the eRx space, a crucial area for future growth in the ePharmacy market. 

HSBC indicates that, if this trend continues, Redcare Pharmacy could continue to outgrow DocMorris in the eRx segment, further solidifying its market leadership​.

On the other hand, DocMorris has been facing multiple headwinds. HSBC has downgraded the stock to "hold" from "buy," cutting its target price to CHF40 from CHF75. 

DocMorris has struggled with the slower-than-expected ramp-up in eRx adoption, and its higher-than-anticipated investment in customer growth has weighed on its profitability. 

“For now, we expect the bigger profitability impact to be on DOCM (rather than RDC), pushing back the path to adj. EBITDA break-even by one year from 2025e to early 2026e,” the analysts said. 

HSBC analysts also flag the growing divergence in operational momentum between the two companies. DocMorris has been forced to lower its guidance due to these challenges, further emphasizing the gap between it and Redcare Pharmacy. 

Despite this, DocMorris is not without its potential upside, particularly if it can successfully pivot its strategy and capture greater market share in the eRx space in the long run. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.